EUR 53.4
(2.5%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 23.73 Million EUR | -20.36% |
2022 | 29.8 Million EUR | 24.49% |
2021 | 23.93 Million EUR | 573.84% |
2020 | 3.55 Million EUR | 9.87% |
2019 | 3.23 Million EUR | -72.12% |
2018 | 11.59 Million EUR | 18.42% |
2017 | 9.79 Million EUR | 19.16% |
2016 | 8.21 Million EUR | 9.41% |
2015 | 7.51 Million EUR | 29.34% |
2014 | 5.8 Million EUR | -11.04% |
2013 | 6.52 Million EUR | 159.99% |
2012 | 2.51 Million EUR | 89.96% |
2011 | 1.32 Million EUR | 24.48% |
2010 | 1.06 Million EUR | 464.95% |
2009 | 188 Thousand EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 19.89 Million EUR | 0.0% |
2023 Q2 | 11.15 Million EUR | 0.0% |
2023 Q4 | 12.58 Million EUR | 0.0% |
2023 FY | 23.73 Million EUR | -20.36% |
2022 FY | 29.8 Million EUR | 24.49% |
2022 Q2 | 13.68 Million EUR | 0.0% |
2022 Q4 | 16.11 Million EUR | 0.0% |
2021 Q2 | 2.02 Million EUR | 0.0% |
2021 Q4 | 3.02 Million EUR | 0.0% |
2021 FY | 23.93 Million EUR | 573.84% |
2020 Q4 | 1.82 Million EUR | 0.0% |
2020 FY | 3.55 Million EUR | 9.87% |
2020 Q2 | 1.72 Million EUR | 0.0% |
2019 Q2 | 1.35 Million EUR | 0.0% |
2019 FY | 3.23 Million EUR | -72.12% |
2019 Q4 | 1.87 Million EUR | 0.0% |
2018 Q4 | 6.43 Million EUR | 0.0% |
2018 Q2 | 5.16 Million EUR | 0.0% |
2018 FY | 11.59 Million EUR | 18.42% |
2017 Q4 | 4.95 Million EUR | 0.0% |
2017 FY | 9.79 Million EUR | 19.16% |
2017 Q2 | 4.83 Million EUR | 0.0% |
2016 FY | 8.21 Million EUR | 9.41% |
2016 Q2 | 4.08 Million EUR | 0.0% |
2016 Q4 | 4.13 Million EUR | 0.0% |
2015 Q4 | 3.51 Million EUR | 0.0% |
2015 Q2 | 3.99 Million EUR | 0.0% |
2015 FY | 7.51 Million EUR | 29.34% |
2014 FY | 5.8 Million EUR | -11.04% |
2014 Q4 | 2.96 Million EUR | 0.0% |
2014 Q2 | 2.84 Million EUR | 0.0% |
2013 Q3 | 663.56 Thousand EUR | 0.0% |
2013 FY | 6.52 Million EUR | 159.99% |
2013 Q4 | 481.73 Thousand EUR | -27.4% |
2013 Q2 | 663.56 Thousand EUR | 0.0% |
2013 Q1 | 663.56 Thousand EUR | 0.0% |
2012 Q3 | 106.02 Thousand EUR | 0.0% |
2012 Q1 | 106.02 Thousand EUR | 0.0% |
2012 Q4 | 663.56 Thousand EUR | 525.85% |
2012 Q2 | 106.02 Thousand EUR | 0.0% |
2012 FY | 2.51 Million EUR | 89.96% |
2011 Q2 | 5475.00 EUR | 0.0% |
2011 Q1 | 5475.00 EUR | 0.0% |
2011 FY | 1.32 Million EUR | 24.48% |
2011 Q3 | 5475.00 EUR | 0.0% |
2011 Q4 | 106.02 Thousand EUR | 1836.53% |
2010 Q1 | 208.27 Thousand EUR | 0.0% |
2010 FY | 1.06 Million EUR | 464.95% |
2010 Q4 | 5475.00 EUR | -97.37% |
2010 Q3 | 208.27 Thousand EUR | 0.0% |
2010 Q2 | 208.27 Thousand EUR | 0.0% |
2009 Q4 | 208.27 Thousand EUR | 517.12% |
2009 Q2 | 33.75 Thousand EUR | 0.0% |
2009 Q1 | 33.75 Thousand EUR | 0.0% |
2009 Q3 | 33.75 Thousand EUR | 0.0% |
2009 FY | 188 Thousand EUR | 0.0% |
2008 Q4 | 33.75 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BioNTech SE | 2.52 Billion EUR | 99.061% |
CureVac N.V. | 211.75 Million EUR | 88.792% |
Biotest Aktiengesellschaft | 136.8 Million EUR | 82.651% |
Biotest Aktiengesellschaft | 136.8 Million EUR | 82.651% |
BRAIN Biotech AG | 24.94 Million EUR | 4.843% |
Heidelberg Pharma AG | 27.81 Million EUR | 14.678% |
Medigene AG | 20.54 Million EUR | -15.545% |